NEW YORK, Jan. 5, 2017 /PRNewswire/ -- Prognos,
www.prognos.ai, an innovative healthcare AI company, has launched
after six years of development as Medivo. Supported by Merck Global
Health Innovation Fund and Safeguard Scientifics, Inc., the company
strives to improve health by tracking and predicting disease
earlier in partnership with Life Sciences brands, payers, and
clinical diagnostics organizations. Prognos' innovations enhance
the value of laboratory results and clinical diagnostic data
through advanced analytics and artificial intelligence
techniques.
The Prognos Registry of 5 billion clinical records for 100
million patients in over 30 disease areas enables earlier
identification of patients who can benefit from enhanced treatment
decision-making, risk management, and quality improvement under the
HEDIS guidelines. During its research and development phase as
Medivo, Prognos invested in innovations exploring the potential of
clinical diagnostic assets and is now realizing the full value of
those assets through AI and HIPAA-compliant advanced analytics with
over 500 proprietary and learning clinical algorithms.
"The launch of Prognos elevates our ability to leverage the
largest aggregated database of lab results in the U.S. and deliver
actionable clinical insights to the medical community," said
Sundeep Bhan, Prognos Co-Founder and
CEO.
Payer organizations can now take advantage of Prognos' solutions
to engage with providers earlier in the patient treatment process,
improving the overall quality of care. By connecting payers
directly with the lab, Prognos has the added benefit of accessing
clinical diagnostic data on the payer's behalf, enhancing the
resulting insights. Identifying and reaching at-risk patients
earlier can help plans to reduce avoidable care costs, especially
for patients with chronic conditions and comorbidities.
Global health service company Cigna is using Prognos analytics
to improve health engagement among its Individual and Family Plan
customers.
"Prognos' analytics help us identify customers with chronic
conditions such as diabetes, rheumatoid arthritis, and hepatitis C,
so that we can engage them early and support them with health
management options," said Brian
Evanko, president of Cigna's Individual and Family Plans
segment. "This helps drive better health outcomes for our
customers, resulting in improved health care quality and a better
customer experience."
Life Sciences organizations can leverage Prognos products to
determine specific and complex patient journeys and help brands
dependent on biomarkers commercialize highly targeted patient
selection strategies for the treating physicians. Prognos'
"Trigger" solution identifies newly-diagnosed patients and provides
weekly alerts to help brands educate providers on therapy options
before treatment decisions are made. Prognos currently works with
17 Life Sciences organizations.
"We expect Biogen's partnership with Prognos to help us provide
more awareness of the benefits of diagnosing earlier by finding the
right patients based on specific biomarkers," said Justin Bush, US Brand and Launch Lead, Rare
Disease Group at Biogen.
Diagnostics organizations can partner with Prognos to leverage
their lab data and clinical and technology expertise with Prognos
analytic solutions. Such partnerships further the ability of lab
data to inform physicians and increase the likelihood that patients
can access the treatments that will improve their care outcomes.
Current diagnostic collaborators include Quest Diagnostics and
Laboratory Corporation of America Holdings (LabCorp). The
Prognos Registry includes data from hundreds of labs and
diagnostics companies.
About Prognos
Prognos is a healthcare AI company
focused on eradicating disease by driving decisions earlier in
healthcare in collaboration with payers, Life Sciences and
diagnostics companies. The Prognos Registry is the largest source
of clinical diagnostics information in over 30 disease areas, with
over 5B medical records for 100M patients. Prognos has 500
extensive proprietary and learning clinical algorithms to enable
earlier patient identification for enhanced treatment
decision-making, risk management and quality improvement. The
company is supported by a $23M
investment from Safeguard Scientifics, Inc. (NYSE:SFE) and Merck
Global Health Innovation Fund (GHIF). For more information, visit
www.prognos.ai.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/prognos-an-ai-company-launches-to-eradicate-disease-by-driving-decisions-earlier-in-healthcare-300386629.html
SOURCE Prognos